NCT00000159|CompletedPhase 3
Loading search results
Sponsor study identifier
interventional
N/A
0 countries
N/A
Study Start
August 1983
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedTo evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons with insulin-dependent diabetes.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 1983
Date type not reportedThis date has not been verified as actual or estimated.
September 23, 1999
Actual (reported)September 24, 1999
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. Arch Ophthalmol. 1990 Sep;108(9):1234-44. doi: 10.1001/archopht.1990.01070110050024.
The sorbinil retinopathy trial: neuropathy results. Sorbinil Retinopathy Trial Research Group. Neurology. 1993 Jun;43(6):1141-9. doi: 10.1212/wnl.43.6.1141.
First Submitted
September 23, 1999
First Posted
September 24, 1999
Study Start
August 1983
Date type not reportedThis date has not been verified as actual or estimated.
Last Updated
June 24, 2005
Record last verified: 1999-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy